The frequent loss of heterozygosity, the inverse correlation between PTEN dose and tumorigenicity and the variety of PTEN regulatory mechanisms suggest that altering PTEN levels in cells may affect tumor progression, including that of thyroid, breast, and prostate cancer (41, 43–46). The gene discussed is PTEN; the disease is neoplasm.